A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
NCT00159913
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Male or female subjects aged from 1 to 17 years old and weighing >= 8 kg with a mean pulmonary artery pressure >= 25 mmHg at rest, PCWP <= 15 mmHg, and PVRI >= 3 Wood units x m2 (if PCWP is not available, then mean LA pressure <= 15 mmHg or LVEDP <= 15 mmHg in the absence of left atrial obstruction).
- Females of child bearing potential who were sexually active must have been practicing a suitable method of birth control so that in the opinion of the investigator, they would not become pregnant during the study.
- Subjects who have symptomatic pulmonary arterial hypertension due to: primary pulmonary hypertension; pulmonary arterial hypertension in the presence of a small or hemodynamically insignificant congenital systemic to pulmonary shunt lesion that in the opinion of the investigator is not the cause of pulmonary hypertension; collagen vascular disease; congenital systemic-to-pulmonary shunts with a baseline resting room air oxygen saturation >= 88% unrepaired or repaired at least 6 months prior to screening; d-transposition of the great arteries repaired within the first 30 days of life; or surgical repair of other congenital heart lesions at least 6 months prior to screening and do not have clinically significant residual left-sided heart disease consistent with the exclusion criteria.
- Subjects, developmentally able to exercise, whose CPX exercise test functional capacity is within the following parameters: Peak VO2 >= 10 mL/kg/min and <= 28 mL/kg/min during screening CPX test;
- Written informed consent and assent where applicable before the subject is screened for the study.
- Subjects who undergo a large shift in altitude (defined as approximately 5000 feet or 1524 meters) in order to participate in the study must reside at the "in study" altitude for at least 90 days prior to baseline and during the study period.
- Subjects with pulmonary hypertension secondary to sickle cell disease, any other
disease known to be associated with PAH, or any etiology other than those specified in
the inclusion criteria.
- Left-sided heart disease, including aortic or mitral valve disease (greater than
mild), restrictive or congestive cardiomyopathy; PCWP or LVEDP > 15 mmHg; LVEF < 40%
determined by MUGA, angiography or echocardiography; LV shortening fraction < 22%
determined by echocardiography, symptomatic coronary disease (demonstrable ischemia).
- Pericardial constriction; significant (2+ for regurgitation) valvular disease other
than tricuspid or pulmonary regurgitation; acutely decompensated heart failure within
previous 30 days from screening; atrial septostomy within previous 6 months of
screening;
- Hemodynamic instability or hypo- or hypertension at screening, i.e., SBP outside of
70-140 mmHg.
- A history of stroke, myocardial infarction or life threatening arrhythmia within 6
months of screening.
- Moderate to severe restrictive pulmonary disease (Total Lung Capacity or Forced Vital
Capacity <= 60% of normal) or history of severe lung disease.
- Subjects with bronchopulmonary dysplasia (BPD) and other chronic lung diseases.
- History of pulmonary embolism.
- Subjects whose CPX test is limited by conditions other than pulmonary
hypertension-associated dyspnea or fatigue.
- Subjects who are known to be HIV positive
- Subjects with impairment of renal function (serum creatinine > 2.5x ULN ) or hepatic
function (ALT and/or AST > 3x ULN; and/or bilirubin >= 2 mg/dL). Hematological
abnormalities (e.g., severe anemia, Hgb < 10 g/dL, leukopenia, WBC < 2500/mL).
- Subjects who previously received bosentan and whose liver function tests taken at
screening are > 2x ULN.
- Subjects with any medical condition which in the opinion of the investigator may
interfere with treatment, evaluation of safety, and/or efficacy.
- Change in class of medication for CHF or PAH within the 10 days prior to qualifying
right heart catheterization.
- Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in
any form. Acute vasodilator testing with nitric oxide is permitted during hemodynamic
evaluation; taking chronic arginine supplementation including Heart Bar; therapy
involving parenteral inotropic medication or parenteral vasodilators within 3 months
of screening; current therapy with alpha-blockers, potent cytochrome P450 3A4
inhibitors (e.g., erythromycin, ketoconazole, itraconazole and protease inhibitors),
Ritonavir or Nicorandil; chronic treatment with off-label sildenafil, an endothelin
antagonist or prostacyclin/prostacyclin analogue within 30 days of randomization.
- Pregnant or lactating female.
- Any medical or psychological condition or social circumstances that would impair their
ability to participate reliably in the study or who were not likely to complete the
study for any reason; current or past illicit drug use or alcoholism excepting if
abstinence can be documented for >= 1 year.
- Participation in another clinical trial of an investigational drug or device
(including placebo) within 30 days of screening for entry into the present study.
- Subjects with known hereditary degenerative retinal disorders (such as retinitis
pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Palo Alto, California
- Stanford, California
- Aurora, Colorado
- Boston, Massachusetts
- Ann Arbor, Michigan
- St. Louis, Missouri
- New York, New York
- Columbus, Ohio
- Charleston, South Carolina
- Seattle, Washington
- São Paulo, SP
- Edmonton, Alberta
- Santiago, RM
- Medellin, Antioquia
- Bogota, Cundinamarca
- Guatemala,
- Budapest,
- Budapest,
- Deszk,
- Szeged,
- Szeged,
- Hyderabad, Andra Pradesh
- Kerala, Kochi,
- Bologna,
- Tokyo,
- Penang,
- Penang,
- Del. Tlalpan, Mexico D.F.
- Tlalpan, Mexico DF
- Lima,
- Krakow,
- Krakow,
- Warszawa,
- Warszawa,
- Zabrze,
- Moscow,
- Moscow,
- Lund,
- Kaohsiung,
- Taipei,
- Taipei,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension. | |||
Official Title ICMJE | A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension. | |||
Brief Summary | This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years. The purpose of the study is to assess the efficacy, safety, and pharmacokinetics of 16 weeks of chronic treatment with oral sildenafil given in three different doses, compared to placebo (inactive treatment). Efficacy will be measured by exercise and hemodynamics. Patients who complete this trial may be eligible to take part in an extension study, in which all patients will receive active treatment of sildenafil. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Pulmonary Arterial Hypertension, Children | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 235 | |||
Original Enrollment ICMJE | 204 | |||
Actual Study Completion Date ICMJE | June 2008 | |||
Actual Primary Completion Date | June 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 1 Year to 17 Years (Child) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Brazil, Canada, Chile, Colombia, Guatemala, Hungary, India, Italy, Japan, Malaysia, Mexico, Peru, Poland, Russian Federation, Sweden, Taiwan, United States | |||
Removed Location Countries | Australia, Costa Rica, Panama, Singapore | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00159913 | |||
Other Study ID Numbers ICMJE | A1481131 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2021 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |